Clinical significance of decreased serum concentration of cartilage oligomeric matrix protein in systemic juvenile idiopathic arthritis

Journal of Rheumatology

Volumn 33, Issue 5, 2006, Pages 996-1000

  Urakami, Tomoko ^a   Manki, Akira ^a   Inoue, Takuya ^a   Oda, Megumi ^a,b   Tanaka, Hiroyuki ^a   Morishima, Tsuneo ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b OKAYAMA UNIVERSITY MEDICAL SCHOOL   (Japan)

Author keywords

Cartilage oligomeric matrix protein; Growth impairment; Interleukin 6; Juvenile idiopathic arthritis; Systemic juvenile idiopathic arthritis

Indexed keywords

AUROTHIOMALATE; CARTILAGE OLIGOMERIC MATRIX PROTEIN; CYCLOSPORIN A; METHOTREXATE; MIZORIBINE; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISOLONE; SALAZOSULFAPYRIDINE;

ADOLESCENT; ADULT; ARTHRITIS; ARTICLE; CARTILAGE DEGENERATION; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC VALUE; DISEASE MARKER; EARLY DIAGNOSIS; FEMALE; GROWTH DISORDER; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; MALE; OSTEOARTHRITIS; POLYARTHRITIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; SYSTEMIC DISEASE;

ADOLESCENT; ARTHRITIS; ARTHRITIS, JUVENILE RHEUMATOID; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CARTILAGE; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; ENZYME-LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR MATRIX PROTEINS; FEMALE; GLYCOPROTEINS; GROWTH DISORDERS; HUMANS; MALE;

EID: 33646443505     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Muller G, Michel A, Altenburg E. COMP (cartilage oligomeric matrix protein) is synthesized in ligament, tendon, meniscus, and articular cartilage. Connect Tissue Res 1998;39:233-44.
2. DiCesare PE, Morgelin M, Mann K, Paulsson M. Cartilage oligomeric matrix protein and thrombospondin 1. Purification from articular cartilage, electron microscopic structure, and chondrocyte binding. Eur J Biochem 1994;223:927-37.
3. Oldberg A, Antonsson P, Lindblom K, Heinegard D. COMP (cartilage oligomeric matrix protein) is structurally related to the thrombospondins. J Biol Chem 1992;267:22346-50.
4. Recklies AD, Baillargeon L, White C. Regulation of cartilage oligomeric matrix protein synthesis in human synovial cells and articular chondrocytes. Arthritis Rheum 1998;41:997-1006.
5. Petersson IF, Boegard T, Svensson B, Heinegard D, Saxne T. Changes in cartilage and bone metabolism identified by serum markers in early osteoarthritis of the knee joint. Br J Rheumatol 1998;37:46-50.
6. Neidhart M, Muller-Ladner U, Frey W, et al. Increased serum levels of non-collagenous matrix proteins (cartilage oligomeric matrix protein and melanoma inhibitory activity) in marathon runners. Osteoarthritis Cartilage 2000;8:222-9.
7. Saxne T, Glennas A, Kvien TK, Melby K, Heinegard D. Release of cartilage macromolecules into the synovial fluid in patients with acute and prolonged phases of reactive arthritis. Arthritis Rheum 1993;36:20-5.
8. Sharif M, Saxne T, Shepstone L, et al. Relationship between serum cartilage oligomeric matrix protein levels and disease progression in osteoarthritis of the knee joint. Br J Rheumatol 1995;34:306-10.
9. Neidhart M, Hauser N, Paulsson M, DiCesare PE, Michel BA, Hauselmann HJ. Small fragments of cartilage oligomeric matrix protein in synovial fluid and serum as markers for cartilage degradation. Br J Rheumatol 1997;36:1151-60.
10. Kuhne SA, Neidhart M, Everson MP, et al. Persistent high serum levels of cartilage oligomeric matrix protein in a subgroup of patients with traumatic knee injury. Rheumatol Int 1998;18:21-5.
11. Skoumal M, Kolarz G, Klingler A. Serum levels of cartilage oligomeric matrix protein. A predicting factor and a valuable parameter for disease management in rheumatoid arthritis. Scand J Rheumatol 2003;32:156-61.
12. Vilim V, Vytasek R, Olejarova M, et al. Serum cartilage oligomeric matrix protein reflects the presence of clinically diagnosed synovitis in patients with knee osteoarthritis. Osteoarthritis Cartilage 2001;9:612-8.
13. Petty RE, Southwood TR, Baum J, et al. Revision of the proposed classification criteria for juvenile idiopathic arthritis: Durban, 1997. J Rheumatol 1998;25:1991-4.
14. Gattorno M, Vignola S, Falcini F, et al. Serum and synovial fluid concentrations of matrix metalloproteinases 3 and its tissue inhibitor 1 in juvenile idiopathic arthritides. J Rheumatol 2002;29:826-31.
15. Matsuyama T. Tissue inhibitor of metalloproteinases-1 and matrix metalloproteinase-3 in Japanese healthy children and in Kawasaki disease and their clinical usefulness in juvenile rheumatoid arthritis. Pediatr Int 1999;41:239-45.
16. Shigemori M, Takei S, Imanaka H, et al. Diagnostic significance of increased serum hyaluronic acid in juvenile rheumatoid arthritis. Pediatr Int 2002;44:394-9.
17. Rooney M, David J, Symons J, Di Giovine F, Varsani H, Woo P. Inflammatory cytokine responses in juvenile chronic arthritis. Br J Rheumatol 1995;34:454-60.
18. Yokota S. Interleukin 6 as a therapeutic target in systematic-onset juvenile idiopathic arthritis. Curr Opin Rheumatol 2003;15:581-6.
19. De Benedetti F, Mecazza C, Oliveri M, et al. Effect of IL-6 on IGF binding protein-3: a study in IL-6 transgenic mice and in patients with systematic juvenile idiopathic arthritis. Endocrinology 2001;142:4818-26.
20. Nilsson A, Ohlsson C, Isaksson OG, Lindahl A, Isgaard J. Hormonal regulation of longitudinal bone growth. Eur J Clin Nutr 1994:48 Suppl 1:S150-8; discussion S8-60.
21. Saxne T, Heinegard D. Cartilage oligomeric matrix protein: a novel marker of cartilage turnover detectable in synovial fluid and blood. Br J Rheumatol 1992;31:583-91.
22. Bjarnason R, Andersson B, Kim HS, et al. Cartilage oligomeric matrix protein increases in serum after the start of growth hormone treatment in prepubertal children. J Clin Endocrinol Metab 2004;89:5156-60.
23. Forslind K, Eberhardt K, Jonsson A, Saxne T. Increased serum concentrations of cartilage oligomeric matrix protein. A prognostic marker in early rheumatoid arthritis. Br J Rheumatol 1992;31:593-8.
24. De Benedetti F, Alonzi T, Moretta A, et al. Interleukin 6 causes growth impairment in transgenic mice through a decrease in insulin-like growth factor-1. A model for stunted growth in children with chronic inflammation. J Clin Invest 1997;99:643-50.
25. Martensson K, Chrysis D, Savendahl L. Interleukin-1 beta and TNF-alpha act in synergy to inhibit longitudinal growth in fetal rat metatarsal bones. J Bone Miner Res 2004;19:1805-12.
26. Liem JJ, Rosenberg AM. Growth patterns in juvenile rheumatoid arthritis. Clin Exp Rheumatol 2003;21:663-8.
27. Simon D, Fernando C, Czernichow P, Prieur AM. Linear growth and final height in patients with systematic juvenile idiopathic arthritis treated with longterm glucocorticoids. J Rheumatol 2002;29:1296-300.